Erdafitinib for the treatment of metastatic bladder cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures [Internet] Atlanta: American Cancer Society; [updated 2019; cited Jun 2019]. Available from: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html
   Google Scholar
• von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20;23(21):4602–4608.
   PubMed Web of Science ®Google Scholar
• NCCN. The NCCN clinical practical guidelines in oncology bladder cancer (Version 3.2019- April 23 2019). [cited 2019 Jun 26]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
   Google Scholar
• McConkey DJ, Choi W, Shen Y, et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol. 2016 May;69(5):855–862.
   PubMed Web of Science ®Google Scholar
• Mo Q, Nikolos F, Chen F, et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst. 2018 May 1;110(5):448–459.
   PubMedGoogle Scholar
• Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10;25(2):152–165.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19;171(3):540–556 e25.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Vida A, Lerner SP, Bellmunt J. The cancer genome atlas project in bladder cancer. Cancer Treat Res. 2018;175:259–271.
   PubMedGoogle Scholar
• Marzouka NA, Eriksson P, Rovira C, et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018 Feb 27;8(1):3737.
   PubMed Web of Science ®Google Scholar
• Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110–3115.
   PubMed Web of Science ®Google Scholar
• Rebouissou S, Bernard-Pierrot I, de Reynies A, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6:244ra91, United States: American Association for the Advancement of Science
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Choi W, Ochoa A, et al. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr;29(2):377–94, x-xi.
   PubMed Web of Science ®Google Scholar
• FDA, Resources for information on approved drugs. [cited 2019 Jun]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma
   Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–1492.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–322.
   PubMed Web of Science ®Google Scholar
• Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51–64.
   PubMed Web of Science ®Google Scholar
• Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017 Sep 14;3(9):e172411.
   PubMed Web of Science ®Google Scholar
• Heery CR, O’Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–598.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.
   PubMed Web of Science ®Google Scholar
• Grunewald S, Politz O, Bender S, et al. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346–1357.
   PubMed Web of Science ®Google Scholar
• Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018 Jul;8(7):812–821.
   PubMed Web of Science ®Google Scholar
• Joerger M, Cassier PA, Penel N, et al. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. Journal of Clinical Oncology. 2018;36(15_suppl):4513–4513.
   Google Scholar
• Necchi APD, Pouessel D, Leibowitz-Amit R, et al. Interim results of fight-201, a phase 2, open-label, multicenter study of INCB054828 dosed intermittently in patients with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations. Poster presented at: ESMO 2018 Congress; 2018 October 19–23; Munich (Germany).
   Google Scholar
• Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 Jul 05;10(1):2977.
   PubMed Web of Science ®Google Scholar
• Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol. 2017 Jan 10;35(2):157–165.
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Currie G, Abella E, et al. FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. Poster presented at: ASCO 2019 Annual Meeting; 2019 May 31-June 4; Chicago (IL).
   Google Scholar
• Petrylak DP, Balar AV, O’Donnell PH, et al. EV-201: results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. J Clin Oncol. 2019;37(18_suppl):4505.
   Web of Science ®Google Scholar
• Tagawa ST, Faltas BM, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I/II study. J Clin Oncol. 2019;37(7_suppl):354.
   Web of Science ®Google Scholar
• Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011 Jul 15;437(2):199–213.
   PubMed Web of Science ®Google Scholar
• Wohrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011 Oct;26(10):2486–2497.
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009 Mar;8(3):235–253.
   PubMed Web of Science ®Google Scholar
• Li F, Huynh H, Li X, et al. FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 2015 Apr;5(4):438–451.
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010 Dec 15;2(62):62ra93.
   PubMed Web of Science ®Google Scholar
• Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001 May 1;61(9):3541–3543.
   PubMed Web of Science ®Google Scholar
• Guancial EA, Werner L, Bellmunt J, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug;3(4):835–844.
   PubMed Web of Science ®Google Scholar
• Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010 Apr 8;29(14):2013–2023.
   PubMed Web of Science ®Google Scholar
• Karkera JD, Cardona GM, Bell K, et al. Oncogenic characterization and pharmacologic sensitivity of activating Fibroblast Growth Factor Receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. Mol Cancer Ther. 2017 Aug;16(8):1717–1726.
   PubMed Web of Science ®Google Scholar
• Li Q, Bagrodia A, Cha EK, et al. Prognostic genetic signatures in upper tract urothelial carcinoma. Curr Urol Rep. 2016 Feb;17(2):12.
   PubMed Web of Science ®Google Scholar
• Therapeutics. Astex announces new drug discovery collaboration with University of Newcastle upon tyne and cancer research technology limited [media release]. 2006 Mar 13 [Internet]. [cited 2019 July 30]. Available from: http://www.astex-therapeutics.com
   Google Scholar
• Astex Therapeutics. Astex announces new drug discovery alliance with Janssen Pharmaceutica N.V [media release]. 2008 Jun 9 [Internet]. [cited 2019 July 30]. Available from: http://www.astex-therapeutics.com
   Google Scholar
• Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017 Jun;16(6):1010–1020.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015 Oct 20;33(30):3401–3408.
   PubMed Web of Science ®Google Scholar
• FDA, Janssen Pharmaceuticals. BALVERSATM (erdafitinib): US prescribing information. 2019. [cited 2019 Jul]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf
   Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338–348.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first targeted therapy for metastatic bladder cancer [media release]. 2019 Apr 12. [Internet]. [cited 2019 July 30]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635906.htm.
   Google Scholar
• Wang L, Gong Y, Saci A, et al. Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. 2019 Jul 1;76:599–603.
   Web of Science ®Google Scholar
• Hoffman-Censits JH, Grivas P, Heijden MSVD, et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J Clin Oncol. 2016;34(2_suppl):355.
   Web of Science ®Google Scholar